Home > About us

SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line.

SYnAbs' vision is to fill the gap on the marketplace for innovative monoclonal antibodies against poor immunogenic compounds and complex homologous antigens. Targeting transmembrane proteins (GPCRs, ion channels, transporters), steroids, small molecules, toxins, lipids and polysaccharides (on fungi and bacteria), SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat-LOU species to generate unique monoclonal antibodies of extreme specificity and higher affinity.

In order to address the challenge of raising innovative monoclonals against haptens and membrane proteins, SYnAbs has developed a set of technologies, combining :

• Innovative antigen design via proprietary assets such as SYnDNA vector, SYnCell syngeneic cell lines and in-house adjuvant
• Multi-species immunization in proprietary rat-LOU species, wild type, Knock-out and multiple transgenic species including ATX-Gx transgenic mouse platform
• Strategic immunization to break immune tolerance and trigger specific epitopes
• Selection and isolation of rare B cell populations.

Our technologies ensure the generation of high specificity and greater affinity antibodies, benefiting from natural in-vivo maturation and targeting antigens that are difficult to express in native and functionally active conformation.

The unique expertise of SYnAbs team has allow us to generate unique monoclonal antibodies on the marketplace, bringing added value in the fields of cancer immunotherapy, endocrinology and auto-immune diseases. You'll find here a few examples.

SYnAbs SA is involved in the production of rat monoclonal antibodies, serving Biotech, Pharma and In-Vitro Diagnostic companies with a large catalogue of secondary monoclonal antibodies (more than a hundred secondary anti-immunoglobulins) and unique primary monoclonal antibodies that has gained strong international recognition.

Thanks to its scientists and unique technologies, SynAbs offer a one-stop-shop portfolio of services, covering the antigen synthesis and the hapten-carriers chemistry, DNA and cell immunization, up to the custom generation and manufacturing of gram levels of these mouse and rat monoclonal antibodies.

This unique multi-species immunisation platform enables SynAbs to increase the probability getting the unique monoclonal you’re looking for, and therefore maximizes the success rate of our clients !